Skip to main content

Table 1 Patients demographics

From: Oncologic outcomes after immediate breast reconstruction following mastectomy: comparison of implant and flap using propensity score matching

Characteristics

Reconstruction type

p-value

Implant* (n = 247)

Flap (n = 249)

Age, years

   

0.190

Average

41 ± 8.73

43 ± 6.99

 

Diagnosis

   

0.076

IDC

164

172

 

DCIS

46

50

 

ILD

17

8

 

LCIS

0

4

 

Mixed

11

8

 

Others

9

7

 

Mastectomy type

   

0.151

TM

115

107

 

SSM

64

84

 

NSM

68

58

 

Excised breast mass, gram

   

0.264

Average

367 ± 191.63

409 ± 510.13

 

Lymph node status

   

0.782

N0

180

171

 

N1

43

51

 

N2

16

18

 

N3

8

9

 

AJCC Stage

   

0.278

0

47

57

 

IA

99

82

 

IB

1

0

 

IIA

49

53

 

IIB

24

26

 

IIIA

20

19

 

IIIB

0

3

 

IIIC

7

9

 

Chemotherapy

   

0.647

none

111

117

 

perioperative

136

132

 

Radiotherapy

   

0.702

none

195

200

 

adjuvant

51

48

 

Nuclear grade, no. (%)

   

0.487

1

4

4

 

2

101

84

 

3

94

100

 

Histological grade, no. (%)

   

0.896

1

16

14

 

2

104

95

 

3

74

74

 

ER, no. (%)

   

0.462

Negative

49

43

 

Positive

198

206

 

PR, no. (%)

   

0.952

Negative

76

76

 

Positive

171

173

 

HER2, no. (%)

   

0.128

Negative

174

193

 

Positive

56

44

 

Ki67, no. (%)

   

0.014

< 10%

198

174

 

≥10%

48

71

 
  1. IDC invasive ductal carcinoma; ILC invasive lobular carcinoma; DCIS ductal carcinoma in situ; LCIS lobular carcinoma in situ; TM total mastectomy; SSM skin-sparing mastectomy; NSM nipple-sparing mastectomy; AJCC American Joint Committee on Cancer; ER estrogen receptor; PR progesterone receptor; HER2 human epidermal growth factor receptor-2
  2. *Implant group includes patients who received reconstruction with tissue expander